Trevi Therapeutics, Inc. (TRVI) Debt-to-equity % [USD] 2021 - 2024

Historical data

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Trevi Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from 2021 to 2024.
Trevi Therapeutics, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 7.44 %, a 59.3% decline year-over-year.

Debt-to-equity, Quarterly (% [USD])

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q1 2024	7.44	-10.8	-59.3%	Mar 31, 2024
Q4 2023	9.08	-16.9	-65%	Dec 31, 2023
Q3 2023	10.7	-30	-73.7%	Sep 30, 2023
Q2 2023	13.1	-69.8	-84.2%	Jun 30, 2023
Q1 2023	18.3	-128	-87.5%	Mar 31, 2023
Q4 2022	26	-91.7	-77.9%	Dec 31, 2022
Q3 2022	40.8	-60	-59.5%	Sep 30, 2022
Q2 2022	82.9			Jun 30, 2022
Q1 2022	146			Mar 31, 2022
Q4 2021	118			Dec 31, 2021
Q3 2021	101			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.